Centenial Surgical Suture Share Price Today | Stock Price & Centenial Surgical Suture Share Screener
As of November 19, 2026, the live Centenial Surgical Suture share price (BSE: CSURGSU) is ₹95.84, up 5.00% from the previous close, with shares trading between ₹95.84 and ₹95.84 in today's trading session, and a 52-week range of ₹67.95–₹114.15. Track CSURGSU market cap trends to gauge the company's total market size. Use the Centenial Surgical Suture stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Centenial Surgical Suture opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹57 and net income of ₹-1, with EBITDA of ₹7, an operating margin of 12.0% and a profit margin of -1.8%.
Centenial Surgical Suture Share Price Chart
Track the current stock price of Centenial Surgical Suture with an interactive chart. Analyse CSURGSU share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Centenial Surgical Suture stock quote in one place.
The quote of ₹95.84 sits between the 52-week low of ₹67.95 and the 52-week high of ₹114.15, and the latest session moved 5.00% from the previous close.
Centenial Surgical Suture Company Profile - Fundamental Screener
Screen Centenial Surgical Suture company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for CSURGSU shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Healthcare Equipment & Supplies industry, and it trades under ISIN INE405H01018.
Company Details
Classification
Identifiers and Leadership
Centenial Surgical Suture Balance Sheet Screener
Screen CSURGSU balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹80, down from ₹85 in 2025.
Latest statistics put total assets at ₹80 and shareholder funds at ₹29, with a leverage ratio of 0.97.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 80 | 85 | 79 | 66 | 61 | 70 | 69 | 57 | 55 | 56 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 18 | 20 | 13 | 7 | 8 | 9 | 10 | 4 | 4 | 4 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 20 | 22 | 14 | 6 | 7 | 9 | 10 | 3 | 3 | 3 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 29 | 31 | 32 | 31 | 30 | 30 | 29 | 28 | 26 | 25 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 23 | 25 | 27 | 26 | 25 | 24 | 23 | 23 | 21 | 19 |
Centenial Surgical Suture Income Statement Screener - Profit & Revenue Analysis
Screen Centenial Surgical Suture income statement and profit fundamentals. Analyze CSURGSU quarterly results. Centenial Surgical Suture reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹57 and net profit was ₹-1, equal to earnings per unit of ₹-2.10, at an operating margin of 12%.
In that period expenses were ₹50, interest cost ₹3 and tax ₹1. The next period listed, 2026-March, shows revenue of ₹54 and net profit of ₹-2.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 57 | 54 | 54 | 51 | 53 | 45 | 37 | 56 | 56 | 53 | 53 | 52 | 52 |
| Expenses | 50 | 49 | 47 | 46 | 48 | 40 | 32 | 50 | 51 | 48 | 48 | 47 | 47 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 7 | 5 | 6 | 5 | 4 | 5 | 5 | 6 | 5 | 5 | 5 | 5 | 5 |
| Operating Profit % | 12.00% | 9.00% | 12.00% | 10.00% | 8.00% | 10.00% | 14.00% | 10.00% | 9.00% | 8.00% | 9.00% | 9.00% | 10.00% |
| Depreciation | 4 | 4 | 4 | 1 | 1 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Interest | 3 | 3 | 4 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 0 | -2 | -2 | 1 | 2 | 1 | 2 | 2 | 3 | 2 | 3 | 2 | 3 |
| Tax | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Profit | -1 | -2 | -2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| EPS | -2.10 | -6.04 | -4.01 | 3.11 | 2.43 | 1.72 | 2.64 | 3.55 | 5.53 | 4.23 | 4.71 | 4.28 | 5.25 |
Centenial Surgical Suture Cash Flow Screener - Liquidity Fundamentals
Screen CSURGSU cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities generated ₹7.
Over the same period, investing activities used ₹2 and financing activities used ₹5.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 7 | 17 | 6 | 1 | 5 | 2 | 2 | 2 | 2 | 0 |
| Investing Activities | -2 | -12 | -8 | 0 | 0 | -1 | -1 | -1 | -1 | -2 |
Financing and Net Cash | ||||||||||
| Financing Activities | -5 | -6 | 2 | -1 | -5 | -1 | 0 | -1 | -1 | 2 |
| Net Cash Flow | 0 | -1 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 |
Centenial Surgical Suture Shareholding Pattern Screener
See Centenial Surgical Suture shareholding pattern with promoter, FII, and DII holdings. Check Centenial Surgical Suture promoter holding and ownership changes for CSURGSU on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 46.89%, foreign institutions 0.00%, domestic institutions 0.00% and the public 50.69%, spread across 1,182 shareholders.
The shareholder count was 1,182 in 2026-Mar, compared with 1,165 in 2026-Jun.
| Item | 2026-Mar | 2026-Jun | 2026-Sept | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% | 46.89% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 50.69% | 50.71% | 50.71% | 50.29% | 50.29% | 50.64% | 50.70% | 51.68% |
| Other Holding | 2.43% | 2.40% | 2.41% | 2.83% | 2.82% | 2.47% | 2.41% | 1.43% |
| Shareholder Count | 1,182 | 1,165 | 1,183 | 1,206 | 1,186 | 1,193 | 1,200 | 1,072 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Centenial Surgical Suture. Centenial Surgical Suture dividend yield can be compared with peers and other stocks in the market.
Centenial Surgical Suture Stock Index Membership - Nifty & Sensex
See which indices include Centenial Surgical Suture stock. Check CSURGSU index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Centenial Surgical Suture Market Events Screener - Corporate Actions
Get Centenial Surgical Suture corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Centenial Surgical Suture stock events that may affect CSURGSU share price, along with derivatives, futures and options activity and sector gainers.
12 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 12, 2026, with a record date of November 12, 2026.
It is followed by Annual General Meeting dated September 28, 2026 and Quarterly Result Announcement dated August 14, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-12 | 2026-11-12 | Quarterly Result Announcement | NA | 1.45% |
| 2026-09-28 | 2026-09-28 | Annual General Meeting | NA | 21.81% |
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 12.44% |
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | 0.99% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 9.51% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | 3.62% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 5.12% |
| 2025-07-28 | 2025-07-28 | Annual General Meeting | NA | 9.28% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 1.32% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -10.16% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | -8.02% |
| 2024-09-27 | 2024-09-27 | Annual General Meeting | NA | 19.91% |
Centenial Surgical Suture Competitors Screener - Peer Stocks Comparison
Screen CSURGSU competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Molbio Diagnostics | 17,129 | 121.60 | 1,455 | 41.57% | 164 | 60.75 |
| Poly Medicure | 17,072 | 53.80 | 1,995 | 13.43% | 321 | 64.63 |
| Sahajanand Medical Technologies | 5,522 | 78.70 | 1,219 | 17.64% | 69 | 75.49 |
| Tarsons Products | 1,651 | 226.00 | 447 | 9.38% | 14 | 47.58 |
| Laxmi Dental | 1,099 | 34.60 | 286 | 18.15% | 26 | 57.90 |
| Q-Line Biotech | 1,026 | 20.40 | 347 | 7.89% | 56 | 30.31 |
| Hemant Surgical Industries | 936 | 51.00 | 238 | 112.99% | 18 | 63.65 |
| Vasa Denticity | 846 | 69.90 | 283 | 12.77% | 10 | 65.05 |
| Osel Devices | 656 | 23.40 | 295 | 57.88% | 29 | 50.35 |
| Fabtech Technologies | 609 | 17.50 | 431 | 28.40% | 38 | 53.39 |
Centenial Surgical Suture Company Announcements - News & Reports Screener
Screen CSURGSU latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 19, 2026.
The next most recent announcements are dated November 17, 2026 and November 17, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-19 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-11-17 | Standalone Un-Audited Financial Results Of The Company For The Quarter And Half Year Ended September 30 2026 | - |
| 2026-11-17 | Board Meeting Outcome for Outcome Of The Board Meeting Held On November 12 2026 Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements [LODR]) Regulations 2015 | - |
| 2026-11-05 | Board Meeting Intimation for Approval Of Standalone Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2026 Pursuant To Regulation 29 Read With Regulation 33 Of SEBI (LODR) Regulation 2015 | - |
| 2026-10-26 | Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise | - |
| 2026-10-21 | Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise | - |
| 2026-10-19 | Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise | - |
| 2026-10-11 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-05 | Announcement under Regulation 30 (LODR)-Resignation of Director | - |
| 2026-09-28 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | - |
| 2026-09-28 | Shareholder Meeting / Postal Ballot-Outcome of AGM | - |
| 2026-09-19 | Closure of Trading Window | - |
| 2026-09-11 | Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO) | - |
| 2026-09-03 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-09-01 | Reg. 34 (1) Annual Report. | - |
| 2026-09-01 | Intimation Of AGM & Submission Of Notice Of 31St AGM To Be Held On Monday September 28 2026 | - |
| 2026-09-01 | Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations 2015 In Terms Of The Requirements Of Regulation 36(1)(B) - Letter Issued To Non-Emailholders Providing The Web-Link From Where The Notice Of 31St AGM & Annual Report For The FY 2025-26 | - |
| 2026-08-26 | Price Of The Scrip Of Our Company Has Seen An Abnormal Price Rise | - |
| 2026-08-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-08-14 | Intimation Of 31St Annual General Meeting (AGM) Of The Company Cut-Off Date For Voting And E-Voting As Per Regulation 44 Of The SEBI (Listing Obligations And Disclosures Requirements [LODR]) Regulations 2015. | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹95.84, within a 52-week range of ₹67.95 to ₹114.15. The P/E ratio is -38.70 and the P/B ratio is 1.02, with earnings per unit of ₹-6.04. Market capitalisation stands at ₹30.24 Cr. The company operates in the Healthcare sector, in the Healthcare Equipment & Supplies industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.